Posts tagged NASDAQ:EIGR
Eiger completes enrollment in Phase 2 ULTRA study

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54 patients were enrolled across sites in the U.S. and Australia.

Read More
Eiger BioPharma names Dr. David Apelian as COO, EMO

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.

Read More
BTIG starts Eiger BioPharma at buy

BTIG initiated coverage of Eiger BioPharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $32 price target. The stock closed at $7.45 on July 13.

Read More